Dongwha Pharm Introduces 'Ecrac Gel' for Axillary Hyperhidrosis Treatment

Dongwha Pharm announced on the 2nd that it has signed a domestic sales contract for the topical primary axillary hyperhidrosis treatment ‘ECCLOCK Gel’ with Japan’s Kaken Pharmaceutical. Under this contract, Dongwha Pharm will exclusively supply ECCLOCK Gel, apply for domestic approval, and proceed with sales, introducing it to Korea for the first time.

Primary axillary hyperhidrosis treatment 'Ecrac Gel' developed by Kaken Pharmaceutical and introduced by Dongwha Pharm [Photo by Kaken Pharmaceutical]

Launched in Japan in 2020, ECCLOCK Gel is a new drug named by combining ‘ECC’ from eccrine sweat glands, which regulate body temperature, and ‘block,’ meaning to block. Unlike over-the-counter aluminum chloride products that physically block sweat glands by forming a barrier on the epidermal layer of sweat glands, it is a gel-type prescription drug with the anticholinergic agent ‘Sofpironium Bromide’ as its main ingredient.

ECCLOCK Gel has excellent binding affinity to muscarinic receptors of eccrine sweat glands, inhibiting acetylcholine binding and suppressing sweat secretion. Observational studies showed rapid improvement of hyperhidrosis symptoms within one week, and long-term clinical results confirmed effectiveness maintained for 52 weeks. It is especially convenient as it is applied once daily, and its twist-type container allows one dose to be pumped out at the top of the product with a single twist.

A Dongwha Pharm official stated, “There was no suitable treatment method available before moving on to procedures for hyperhidrosis patients,” adding, “Upon domestic introduction, ECCLOCK Gel is expected to become a new first-line treatment option for primary axillary hyperhidrosis.”

Primary focal hyperhidrosis is a condition characterized by excessive sweating in areas such as the hands, feet, armpits, and face, causing emotional and social distress that interferes with daily life. When it occurs in the armpits, it is called ‘primary axillary hyperhidrosis.’

This content was produced with the assistance of AI translation services.